DK1115404T3 - Anvendelse af prostanoid-antagonister til bekæmpelse af primære hovedpiner - Google Patents
Anvendelse af prostanoid-antagonister til bekæmpelse af primære hovedpinerInfo
- Publication number
- DK1115404T3 DK1115404T3 DK98944111T DK98944111T DK1115404T3 DK 1115404 T3 DK1115404 T3 DK 1115404T3 DK 98944111 T DK98944111 T DK 98944111T DK 98944111 T DK98944111 T DK 98944111T DK 1115404 T3 DK1115404 T3 DK 1115404T3
- Authority
- DK
- Denmark
- Prior art keywords
- antagonists
- primary headaches
- single bond
- lower alkyl
- prostanoid antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 206010019233 Headaches Diseases 0.000 title 1
- 231100000869 headache Toxicity 0.000 title 1
- 229940127293 prostanoid Drugs 0.000 title 1
- 150000003814 prostanoids Chemical class 0.000 title 1
- 101150109738 Ptger4 gene Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000018238 Primary Headache disease Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000003851 azoles Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2807—Headache; Migraine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Slide Fasteners, Snap Fasteners, And Hook Fasteners (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9720270.9A GB9720270D0 (en) | 1997-09-25 | 1997-09-25 | Medicaments for the treatment of migraine |
| PCT/GB1998/002895 WO2000018405A1 (en) | 1997-09-25 | 1998-09-25 | Use of prostanoid antagonists for the treatment of primary headache disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1115404T3 true DK1115404T3 (da) | 2004-04-13 |
Family
ID=26312305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98944111T DK1115404T3 (da) | 1997-09-25 | 1998-09-25 | Anvendelse af prostanoid-antagonister til bekæmpelse af primære hovedpiner |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8513027B2 (da) |
| EP (1) | EP1115404B1 (da) |
| JP (1) | JP2002525327A (da) |
| AT (1) | ATE257707T1 (da) |
| AU (1) | AU757265B2 (da) |
| CA (1) | CA2345248C (da) |
| DE (1) | DE69821142T2 (da) |
| DK (1) | DK1115404T3 (da) |
| ES (1) | ES2213914T3 (da) |
| GB (2) | GB9720270D0 (da) |
| PT (1) | PT1115404E (da) |
| WO (1) | WO2000018405A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9720270D0 (en) | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| AU2000234451B2 (en) * | 2000-03-24 | 2005-09-29 | Asterand Uk Acquisition Limited | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| JP2005511562A (ja) * | 2001-10-31 | 2005-04-28 | メディカル リサーチ カウンシル | 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト |
| CN100352506C (zh) * | 2002-02-26 | 2007-12-05 | 奥索-麦克尼尔药品公司 | 抗惊厥剂衍生物和抗偏头痛药物联合的制药用途 |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US20150126573A1 (en) | 2012-05-09 | 2015-05-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2028805B (en) | 1978-07-11 | 1982-11-03 | Glaxo Group Ltd | Prostanoid compounds |
| JPS5718671A (en) | 1980-04-30 | 1982-01-30 | Glaxo Group Ltd | Aminocyclopentane alkenoic acid and esters thereof,manufacture and drug composition |
| US4839384A (en) | 1988-10-07 | 1989-06-13 | E. R. Squibb & Sons, Inc. | Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist |
| US5182272A (en) | 1991-05-03 | 1993-01-26 | G. D. Searle & Co. | 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain |
| ES2149305T3 (es) | 1991-05-03 | 2000-11-01 | Searle & Co | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso. |
| US5212169A (en) | 1991-10-31 | 1993-05-18 | G. D. Searle & Co. | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain |
| EP0613472A1 (en) | 1991-11-05 | 1994-09-07 | G.D. Searle & Co. | 10-acyl-dibenz(b,f) (1,4)-oxazepines and their thiazepines analo gues useful as prostaglandin antagonists |
| WO1993013082A1 (en) | 1991-12-20 | 1993-07-08 | G.D. Searle & Co. | Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin e2 antagonists |
| US5266571A (en) | 1992-01-09 | 1993-11-30 | Amer Moh Samir | Treatment of hemorrhoids with 5-HT2 antagonists |
| US5395932A (en) | 1993-04-30 | 1995-03-07 | G. D. Searle & Co. | 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
| US5488046A (en) | 1993-11-03 | 1996-01-30 | G. D. Searle & Co. | Carbamic acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| CA2179399A1 (en) | 1993-12-20 | 1995-06-29 | Kiyoshi Taniguchi | 4,5-diaryloxazole derivatives |
| JP3245864B2 (ja) | 1994-03-10 | 2002-01-15 | 藤沢薬品工業株式会社 | プロスタグランジンｉ２アゴニストとしてのナフタレン誘導体 |
| TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
| AUPO713297A0 (en) | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
| GB9720270D0 (en) | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| US20030158240A1 (en) | 1998-09-25 | 2003-08-21 | Pharmagene Laboratories Limited | Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment |
| EP1071648A2 (en) | 1998-03-13 | 2001-01-31 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| WO2000021532A1 (en) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
| ES2274378T3 (es) | 1999-08-10 | 2007-05-16 | Glaxo Group Limited | Ligando del receptor ep4 y uso contra dolor neuropatico, cancer de colon,hiv y migraña. |
| EP1742662A2 (en) | 2004-05-03 | 2007-01-17 | Astellas Pharma Inc. | Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases |
-
1997
- 1997-09-25 GB GBGB9720270.9A patent/GB9720270D0/en not_active Ceased
-
1998
- 1998-09-25 JP JP2000571923A patent/JP2002525327A/ja active Pending
- 1998-09-25 AU AU91776/98A patent/AU757265B2/en not_active Ceased
- 1998-09-25 PT PT98944111T patent/PT1115404E/pt unknown
- 1998-09-25 AT AT98944111T patent/ATE257707T1/de active
- 1998-09-25 DE DE69821142T patent/DE69821142T2/de not_active Expired - Lifetime
- 1998-09-25 CA CA002345248A patent/CA2345248C/en not_active Expired - Fee Related
- 1998-09-25 WO PCT/GB1998/002895 patent/WO2000018405A1/en not_active Ceased
- 1998-09-25 ES ES98944111T patent/ES2213914T3/es not_active Expired - Lifetime
- 1998-09-25 EP EP98944111A patent/EP1115404B1/en not_active Expired - Lifetime
- 1998-09-25 GB GB9820936A patent/GB2341799B/en not_active Expired - Fee Related
- 1998-09-25 DK DK98944111T patent/DK1115404T3/da active
-
2007
- 2007-10-30 US US11/976,945 patent/US8513027B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69821142D1 (de) | 2004-02-19 |
| DE69821142T2 (de) | 2004-11-11 |
| CA2345248A1 (en) | 2000-04-06 |
| EP1115404A1 (en) | 2001-07-18 |
| US20080247954A1 (en) | 2008-10-09 |
| EP1115404B1 (en) | 2004-01-14 |
| AU757265B2 (en) | 2003-02-13 |
| ATE257707T1 (de) | 2004-01-15 |
| GB9720270D0 (en) | 1997-11-26 |
| WO2000018405A1 (en) | 2000-04-06 |
| US8513027B2 (en) | 2013-08-20 |
| GB2341799B (en) | 2000-08-16 |
| PT1115404E (pt) | 2004-05-31 |
| GB9820936D0 (en) | 1998-11-18 |
| GB2341799A (en) | 2000-03-29 |
| JP2002525327A (ja) | 2002-08-13 |
| AU9177698A (en) | 2000-04-17 |
| CA2345248C (en) | 2008-03-18 |
| ES2213914T3 (es) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005013894A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| TW200505903A (en) | CGRP receptor antagonists | |
| CZ305838B6 (cs) | N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6 | |
| MXPA04004457A (es) | Novedosos derivados de 1,2,4-tiadiazolio como moduladores del receptor de melanocortina. | |
| DK1337518T3 (da) | Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren | |
| EA200401157A1 (ru) | N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv | |
| ATE396993T1 (de) | Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität | |
| HRP20090162T1 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
| DE60322877D1 (de) | Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität | |
| WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| AR026352A1 (es) | Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii. | |
| EA200500899A1 (ru) | Антагонисты аденозиндифосфатного рецептора тромбоцитов | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| DK1267867T3 (da) | Anvendelse af prostanoid-EP4-receptorantagonister til behandling af hovedpine og assays til sådanne antagonister | |
| DK1115404T3 (da) | Anvendelse af prostanoid-antagonister til bekæmpelse af primære hovedpiner | |
| DE69922009D1 (de) | Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren | |
| BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
| MXPA05010651A (es) | Compuestos de pirazol. | |
| NO963331L (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| MXPA05010650A (es) | Pirazoles sustituidos. | |
| EA200200727A1 (ru) | Новые производные индола | |
| ZA200500436B (en) | 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |